Safety, immunogenicity, and efficacy of a COVID-19 Vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines

In a sub-study of RCT (n=431), co-administration resulted in no change to influenza vaccine immune response, while a reduction in antibody responses to the NVX-CoV2373 vaccine was noted, with vaccine efficacy in the sub-study of 87.5% (in main study it was 89.8%).

Source:

MedRxiv